Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXZWo9nUUN3ME2wMlYyOjN5IN88US=> MoPNV2FPT0WU
H4 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwNk[yPEDPxE1? M3nnNXNCVkeHUh?=
PA-1 NF:zZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jrR2lEPTB;MD64O|A6PiEQvF2= M1LndXNCVkeHUh?=
NKM-1 M1To[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfSOYZKSzVyPUGuNFQ6OzFizszN MliyV2FPT0WU
NEC8 NH;lTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7UZplRUUN3ME2xMlIyPTd{IN88US=> NXGwVnltW0GQR1XS
EoL-1-cell Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13w[2lEPTB;MT6yOlcxOSEQvF2= M{XDWHNCVkeHUh?=
K5 NH;VZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3OxbGlEPTB;MT60NlA4OiEQvF2= M3ThWXNCVkeHUh?=
QIMR-WIL NFK0WFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC1PFhKUUN3ME2xMlYxQDV2IN88US=> MnPOV2FPT0WU
MOLT-16 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ri[WlEPTB;MT63PFYxPCEQvF2= M2nTPXNCVkeHUh?=
CHP-212 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHS3TI9KSzVyPUGuPFE{PjlizszN MWjTRW5ITVJ?
CTB-1 M1TQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm0d3VKSzVyPUKuNFIzPDZizszN NUjCWlRWW0GQR1XS
MOLT-4 NHvpUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLofnB1UUN3ME2yMlMzQDV|IN88US=> MUjTRW5ITVJ?
A101D M1;MTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLO|VEUUN3ME2yMlM2ODFizszN MXXTRW5ITVJ?
DOHH-2 NUSwNIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrvZWJPUUN3ME2yMlQzOjd7IN88US=> M1mzSnNCVkeHUh?=
ES4 NIXyfpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DTYNKSzVyPUKuOFMyPTVizszN NWLFTppmW0GQR1XS
SW780 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX5UFJKSzVyPUKuOVA5QDNizszN MY\TRW5ITVJ?
VA-ES-BJ M4jBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn2eGdKSzVyPUKuOVQyOSEQvF2= NVvr[VZUW0GQR1XS
RPMI-8866 MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m2VGlEPTB;Mj61OlIyPCEQvF2= Ml;aV2FPT0WU
ML-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV22Sm0zUUN3ME2yMlU3PTd4IN88US=> M{TGT3NCVkeHUh?=
MSTO-211H Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfMTWM2OD1{LkW3OFUyKM7:TR?= NY\6PZZqW0GQR1XS
JVM-3 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Qe3lnUUN3ME2yMlU6OzJ2IN88US=> NH72Rm9USU6JRWK=
A3-KAW NVXyPVdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm1SIVOUUN3ME2yMlYyQDF6IN88US=> NF\PVpZUSU6JRWK=
DK-MG NYf2Z2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXrTWM2OD1{Lk[yOFcyKM7:TR?= MkW4V2FPT0WU
LNCaP-Clone-FGC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XKR2lEPTB;Mj62OFMyQCEQvF2= MkPyV2FPT0WU
HT-144 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T1cmlEPTB;Mj62OFU4PyEQvF2= M3X4e3NCVkeHUh?=
NB69 NEPrbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDLTWM2OD1{Lk[1N|M1KM7:TR?= MV3TRW5ITVJ?
A172 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjlXW5KSzVyPUKuOlc2QDhizszN MnKyV2FPT0WU
RS4-11 NIHnN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwN{K0NFch|ryP M1WyfXNCVkeHUh?=
DU-4475 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJwN{m1NFIh|ryP NF\M[ndUSU6JRWK=
SJSA-1 NV7xSIwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1{LkiyOVU3KM7:TR?= NV;Yb286W0GQR1XS
BV-173 M37JWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Ic4RzUUN3ME2yMlg1PDN7IN88US=> MkHRV2FPT0WU
U-2-OS M3S1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwOUGwO{DPxE1? MVXTRW5ITVJ?
CHP-134 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJwOUO4PFIh|ryP NH7J[2dUSU6JRWK=
D-502MG M3v6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D1OGlEPTB;Mj65O|E2PCEQvF2= Mm\aV2FPT0WU
KS-1 NXjqfmNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mxUmlEPTB;Mz6wNVYzOyEQvF2= NHXJS4tUSU6JRWK=
A204 M33vbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WyVGlEPTB;Mz6wOVU5QCEQvF2= NWTQ[YFkW0GQR1XS
KGN NYTEZ4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwMEi0PVYh|ryP NIPFWVJUSU6JRWK=
NCI-H292 NWHPc2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnTWM2OD1|LkGyNFI5KM7:TR?= MnvDV2FPT0WU
CAKI-1 NVrhT29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PJO2lEPTB;Mz6xNlY6PCEQvF2= M{nZNnNCVkeHUh?=
C2BBe1 NXnHbZBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj0TWM2OD1|LkG3NFI3KM7:TR?= M2izfHNCVkeHUh?=
NB10 NGXnSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMkC5OlYh|ryP NXvFN2ZNW0GQR1XS
MHH-NB-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwMk[4Nlch|ryP NUXuPWZnW0GQR1XS
NCI-SNU-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPTdYpyUUN3ME2zMlI4QDR|IN88US=> Ml7EV2FPT0WU
HCT-116 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET0RZVKSzVyPUOuN|A{OzVizszN M1fFTnNCVkeHUh?=
G-401 M{T3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXEXWpKSzVyPUOuN|Y{OjJizszN MYrTRW5ITVJ?
MN-60 M1u3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHtTWM2OD1|LkS0NFkzKM7:TR?= NFn6TXlUSU6JRWK=
SW982 NUHhRoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNwNUC4OFgh|ryP M3ezUHNCVkeHUh?=
RKO MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3KzdGlEPTB;Mz61N|k{PiEQvF2= NX6yV|J1W0GQR1XS
D-283MED M3nRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvCTWM2OD1|LkW3PVg3KM7:TR?= M1jJNXNCVkeHUh?=
LB996-RCC MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNwNkK1OVgh|ryP NXjWTZJsW0GQR1XS
A549 M4Hje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[2VXZrUUN3ME2zMlY{PTV{IN88US=> MYDTRW5ITVJ?
LB2241-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNwNkW3NFgh|ryP MXvTRW5ITVJ?
SK-HEP-1 NGrScopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\FcZZKSzVyPUOuO|QzQTdizszN NF\Y[HFUSU6JRWK=
G-402 NXjURoMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG3V242UUN3ME2zMlgxQDN{IN88US=> NGrxVWJUSU6JRWK=
GOTO M1XQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwOESzN|Mh|ryP M4LIVHNCVkeHUh?=
LOXIMVI M2LQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTNwOEW2O|Uh|ryP MlXyV2FPT0WU
NH-12 M1jNPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[wTWM2OD12LkCxPVU6KM7:TR?= MULTRW5ITVJ?
CTV-1 NHfV[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PnNWlEPTB;ND6wO|k4OyEQvF2= MofiV2FPT0WU
CP50-MEL-B MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\pcppKSzVyPUSuNlQ{QTJizszN MV7TRW5ITVJ?
RH-18 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrKTWM2OD12LkK3O|A3KM7:TR?= NV31UJhJW0GQR1XS
NB17 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC2PGNKSzVyPUSuN|E4PjhizszN NXPQXIxnW0GQR1XS
A375 NWLmWZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W1b2lEPTB;ND6zN|UzPCEQvF2= MkfrV2FPT0WU
IST-MES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTwTWM2OD12LkSxOFEyKM7:TR?= Mny0V2FPT0WU
MZ2-MEL NH7FVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TVfmlEPTB;ND61NFE2PSEQvF2= M2niU3NCVkeHUh?=
CAL-54 NEfFNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PYOGlEPTB;ND61N|AyQSEQvF2= M3ezfHNCVkeHUh?=
NCI-H28 M{fCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwNkK3NVch|ryP NH\pSWhUSU6JRWK=
D-247MG NF\kbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTFTWM2OD12Lke1NFczKM7:TR?= MlrkV2FPT0WU
NCI-H460 NV\1fnh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z6R2lEPTB;ND65NVEzPyEQvF2= NUXy[os2W0GQR1XS
MCF7 NVnvVHpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf6dWtKSzVyPUWuOFQzPDRizszN MmTQV2FPT0WU
697 NI[wSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwNES1OUDPxE1? M2LtenNCVkeHUh?=
ONS-76 NVf6V29VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m1VWlEPTB;NT61O|AxQSEQvF2= M2S5dXNCVkeHUh?=
C32 M3fUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT5TWM2OD13Lk[wNFI6KM7:TR?= M3PsSHNCVkeHUh?=
OS-RC-2 NH7yXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzLVmxKSzVyPUWuO|M5QDdizszN NGrOPFdUSU6JRWK=
MEL-HO NEToToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzGTWM2OD13Lki1OlY4KM7:TR?= MW\TRW5ITVJ?
LoVo M1O2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZwMEG2NlQh|ryP MVLTRW5ITVJ?
AGS M2LUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\VTWM2OD14LkG0PFI5KM7:TR?= NI\lOWhUSU6JRWK=
GI-ME-N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\YOopKSzVyPU[uNlI1OjFizszN M1zRfXNCVkeHUh?=
H-EMC-SS NUTnV2t{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO2O2M2UUN3ME22MlM5PiEQvF2= NYHDXoY5W0GQR1XS
RVH-421 NUTkU5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrERZB{UUN3ME22MlQzPDJ6IN88US=> MUPTRW5ITVJ?
SW954 NVLrZpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KxOWlEPTB;Nj61OVU4OiEQvF2= NY\XV5I1W0GQR1XS
NB5 M4HWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TXSmlEPTB;Nj61OlE5OyEQvF2= MV7TRW5ITVJ?
NCI-H2122 M17EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi5fW9KSzVyPU[uOVg4QTNizszN MWXTRW5ITVJ?
AM-38 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLyTWM2OD14Lke1OlM6KM7:TR?= M4PLNXNCVkeHUh?=
KNS-81-FD MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTZwN{[0PVQh|ryP MYDTRW5ITVJ?
LS-513 NVezOGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwN{mwNlYh|ryP NYKxZ2FNW0GQR1XS
A427 NIjqU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTuTWM2OD14Lki3PFI6KM7:TR?= NXnRS4trW0GQR1XS
WM-115 M2PnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTZwOUOyN{DPxE1? MWfTRW5ITVJ?
COLO-829 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDMc3dLUUN3ME23MlI1OTh6IN88US=> NWTDSmdtW0GQR1XS
NCI-H1650 MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwM{myNlgh|ryP M{X6c3NCVkeHUh?=
NCI-H358 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT2[IxXUUN3ME23MlQ1QDd7IN88US=> M4nSZnNCVkeHUh?=
HT-1080 M3vwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TNNmlEPTB;Nz60PFI2PCEQvF2= NEexVIRUSU6JRWK=
HCC2218 NUn0cY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTdwNkK5O{DPxE1? MWLTRW5ITVJ?
NCI-H661 NXTUUItIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3i3WGlEPTB;Nz64O|A3QSEQvF2= M3m5c3NCVkeHUh?=
KM-H2 NUfo[GtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq1TWM2OD15Lki4Olk1KM7:TR?= NX\SPXoyW0GQR1XS
RPMI-2650 NGX5XFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdwOUS0NVQh|ryP M3zLRnNCVkeHUh?=
NCI-H226 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnMZWI6UUN3ME24MlIyOTJ{IN88US=> MlLXV2FPT0WU
MKN45 NInXbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7VTWM2OD16LkK2OlAzKM7:TR?= MYPTRW5ITVJ?
D-392MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThwNUK3NlIh|ryP M1PmVnNCVkeHUh?=
RCC10RGB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRThwOE[2PVUh|ryP NYnm[JFkW0GQR1XS
CAL-51 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3VTWM2OD17LkGwNlUyKM7:TR?= NG[4fmtUSU6JRWK=
COLO-678 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTlwM{K4NVEh|ryP NFmy[XNUSU6JRWK=
SK-MEL-24 M3X5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7POGpKSzVyPUmuOVU5PTZizszN NH[wWoFUSU6JRWK=
SK-MEL-30 NW\DSW43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nucmlEPTB;OT65OFQ4PiEQvF2= NI\rR5ZUSU6JRWK=
MMAC-SF NFXHSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nPcGlEPTB;MUCuN|k3OSEQvF2= NXHq[IxCW0GQR1XS
NTERA-S-cl-D1 M1Xmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvaSFF[UUN3ME2xNE43PTB6IN88US=> NWnnUIFbW0GQR1XS
NB12 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\uTWM2OD1zMT61NFMh|ryP NEOwVFlUSU6JRWK=
UACC-257 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFzLki2PVUh|ryP Moq1V2FPT0WU
LAN-6 M{TRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFzLkm5Nlgh|ryP NEHYendUSU6JRWK=
SW1573 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnpZYFyUUN3ME2xNk4{ODh4IN88US=> M1\LSnNCVkeHUh?=
NMC-G1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF{LkSxO|Uh|ryP Mn\yV2FPT0WU
SHP-77 M2LqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW1[Wt3UUN3ME2xNk42PTd2IN88US=> M3TkZnNCVkeHUh?=
IGROV-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL3dW9KSzVyPUGyMlY2PzNizszN MX7TRW5ITVJ?
22RV1 M1yyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmxbnp7UUN3ME2xNk45ODV7IN88US=> NFXnc5dUSU6JRWK=
SK-MEL-3 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe3cJBKSzVyPUGzMlM6PzNizszN NV3xNHFWW0GQR1XS
NCI-H1563 NIDS[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTmTWM2OD1zMz60NlAzKM7:TR?= MV7TRW5ITVJ?
IGR-1 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETEVnlKSzVyPUG0MlA{PDdizszN M2XZNHNCVkeHUh?=
EW-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHxTmtKSzVyPUG0MlE3OzlizszN M4DuUHNCVkeHUh?=
JEG-3 NV6wdW5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHYTWM2OD1zND60PVU{KM7:TR?= NUfrZoR5W0GQR1XS
ES3 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon3TWM2OD1zND62OVYzKM7:TR?= NFXXR29USU6JRWK=
MDA-MB-175-VII Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zcWdKSzVyPUG0MlcyOTFizszN MljLV2FPT0WU
P30-OHK MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF3LkC0PVYh|ryP NFfMdm1USU6JRWK=
GP5d M1\4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17F[2lEPTB;MUWuNVQ3PiEQvF2= MXXTRW5ITVJ?
HMV-II NGjj[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLNeIx{UUN3ME2xOU4{OzN|IN88US=> MVfTRW5ITVJ?
COLO-679 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKyTWM2OD1zNT61NFEh|ryP M2fJSXNCVkeHUh?=
JAR NXzuO25lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLwTWM2OD1zNT63NlA2KM7:TR?= NGfXTpNUSU6JRWK=
NCI-H1666 Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO0O2NKSzVyPUG1Mlk{QTlizszN NHfid45USU6JRWK=
SW48 M{nI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF3Lkm1NVYh|ryP MVPTRW5ITVJ?
NCI-H720 M2K5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3HTWM2OD1zNT65PVg6KM7:TR?= MVTTRW5ITVJ?
HT-1197 M1P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjLSFlKSzVyPUG2MlA{PTJizszN MoPYV2FPT0WU
HL-60 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPNWlEPTB;MU[uNFM5PCEQvF2= MUHTRW5ITVJ?
BEN NIjNcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPWTFFCUUN3ME2xOk42PjN6IN88US=> MmfjV2FPT0WU
HAL-01 M1jHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD3O3ljUUN3ME2xOk45QTB7IN88US=> NX7tbW0xW0GQR1XS
SW900 NIL4PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1TWM2OD1zNj65NVMzKM7:TR?= NV3kfJEyW0GQR1XS
SBC-1 M4LpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly5TWM2OD1zNz61OFI6KM7:TR?= MkDLV2FPT0WU
SH-4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnaZVFrUUN3ME2xO{42QDRzIN88US=> NV\xUWM2W0GQR1XS
UACC-62 NV;ZXI1iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\idZB5UUN3ME2xO{44PjN5IN88US=> NGnQWYFUSU6JRWK=
BHT-101 M1WycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[5VWlEPTB;MUmuPFcxPSEQvF2= NHv5bHJUSU6JRWK=
DB NF;wW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJzLkW2OFkh|ryP NIqxO5hUSU6JRWK=
SK-MEL-1 M174VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7VbVluUUN3ME2yNU42QDd{IN88US=> NXjqcYszW0GQR1XS
NCI-H747 NXzUblV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe3fo5KSzVyPUKyMlc{PzlizszN NWXtemNzW0GQR1XS
SK-LU-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1{Mz6zOVI1KM7:TR?= NYfjW5BpW0GQR1XS
KG-1 M{jV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHhWmx7UUN3ME2yN{41QTR4IN88US=> MULTRW5ITVJ?
LXF-289 M2\xUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17tTmlEPTB;MkOuO|E1KM7:TR?= NX71SXJ6W0GQR1XS
HCC1954 NHXTXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37RRmlEPTB;MkSuPFg1PCEQvF2= M17McXNCVkeHUh?=
Ramos-2G6-4C10 NV;OcJZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITTNZZKSzVyPUK2MlQ6QDFizszN NVTqZogxW0GQR1XS
DBTRG-05MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ4Lk[0PFgh|ryP NFfJN5JUSU6JRWK=
NCI-H2052 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\MTWM2OD1{Nz61Olg1KM7:TR?= M2T1U3NCVkeHUh?=
RMG-I MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJ7LkSxN|kh|ryP M1fzWHNCVkeHUh?=
H9 NHHPUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPyT5pTUUN3ME2zNU4{ODB6IN88US=> MVnTRW5ITVJ?
GR-ST NVrBWZBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN{LkS0OVMh|ryP NEDHNIpUSU6JRWK=
Mo-T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvX[2dEUUN3ME2zNk42ODR4IN88US=> MXLTRW5ITVJ?
SW1088 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf0OmdKSzVyPUOyMlk5ODFizszN Ml\5V2FPT0WU
LB2518-MEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN|LkC3PVch|ryP MkHmV2FPT0WU
NCI-H82 M2\mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN|LkG2OlEh|ryP MoX2V2FPT0WU
LAMA-84 M2HF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLDRWl1UUN3ME2zOE43ODd|IN88US=> M2ficHNCVkeHUh?=
KYSE-450 M2LlZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5RZF1UUN3ME2zOE43Pzd4IN88US=> NVn0OXhmW0GQR1XS
LU-99A MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfTTWM2OD1|NT6wNFA4KM7:TR?= MmHuV2FPT0WU
BE-13 Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjTb|VLUUN3ME2zOU43PTR3IN88US=> M3WxT3NCVkeHUh?=
GAK M4fEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2fWhKSzVyPUO1MlY6PSEQvF2= NGfkWnZUSU6JRWK=
NCI-H1573 NEPU[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTN3Lki4NVgh|ryP M{\DSXNCVkeHUh?=
AsPC-1 M2L1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN4LkG1Nlch|ryP NGfIPIRUSU6JRWK=
HDLM-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHVUlVRUUN3ME2zOk4{OTZizszN NGDHPXBUSU6JRWK=
NCI-H441 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLKTWM2OD1|Nz6wOlkyKM7:TR?= NUfFU3NXW0GQR1XS
CAL-27 M1[0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:5bmlEPTB;M{euO|I{OSEQvF2= NVvrcWJZW0GQR1XS
OVCAR-3 NVfIcpRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjqcGRjUUN3ME2zPU4{OThzIN88US=> NGq4c5dUSU6JRWK=
RPMI-8226 NUHGUWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT4NJpKSzVyPUO5MlU6QCEQvF2= NV:0VmhpW0GQR1XS
EFO-21 NV7VcJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GTWM2OD12MD61PFE1KM7:TR?= M2G5fHNCVkeHUh?=
SNU-C2B MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjobGJKSzVyPUSxMlUxQDRizszN M4nO[nNCVkeHUh?=
VM-CUB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P0ZWlEPTB;NEOuPFA{PyEQvF2= NXPGPY1TW0GQR1XS
NCI-H2087 NHjlVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7w[|B6UUN3ME20OU4xOjN|IN88US=> MkH5V2FPT0WU
EW-16 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\yTWM2OD12Nj6zNVM4KM7:TR?= NXXheGZQW0GQR1XS
SK-N-AS NXnIbmVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rvSWlEPTB;NE[uO|E3PyEQvF2= MVrTRW5ITVJ?
COR-L105 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7UeZN5UUN3ME20Ok45QDV5IN88US=> MXPTRW5ITVJ?
DEL NUXHNJdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WyPWlEPTB;NEiuNFQzQSEQvF2= NUjBSIZ[W0GQR1XS
JVM-2 NF21d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITvTGdKSzVyPUS4MlA2PThizszN Mn3sV2FPT0WU
KARPAS-45 M{jPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HKVWlEPTB;NEmuOFU{QCEQvF2= NVTNRoZSW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID